Cell And Gene Therapy Analytics

  1. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

  2. Applying AI And Rapid Prototyping To Media And Process Development 3/26/2026

    Hear from industry experts on how teams can integrate manufacturability considerations earlier through rapid prototyping, data-driven media development, and predictive modeling.

  3. Quality Control Assays 11/13/2023

    Two company leaders detail not only the vectors their respective companies use and why but also the quality control assays performed on viral vectors.

  4. Advancing Vaccine Development With Novel Chromatography Solutions & Quality Testing 6/24/2025

    Learn more on novel chromatography solutions that can help improve the downstream processes of different vaccine types such as mRNA, recombinant proteins, and Virus-Like Particles (VLPs).

  5. Simple In-House Mycoplasma Testing Method For Regulatory Expectations And Rapid, Confident, And Actionable Results 5/29/2025

    In this webinar, we present an overview of worldwide regulatory guidance for mycoplasma testing, as well as a mycoplasma testing method that has been accepted by regulatory authorities worldwide across various therapeutic modalities.

  6. Next-Gen Disease Models And Cell Therapeutics: Innovations In AI, Omics And Collaboration 8/20/2025

    Learn how to leverage AI, omics integration, and collaborative research to build more physiologically relevant disease models and accelerate the development of next-gen cell therapies.

  7. Implementing Rapid Microbial Identification In Biotherapy Manufacutring 5/27/2025

    Learn about rapid microbial identification strategies that enhance environmental monitoring and compliance with regulatory requirements for your manufacturing processes.

  8. Microbial Identification Via DNA-Seq 6/9/2025

    Learn how DNA sequencing-based microbial identification supports regulatory compliance and enhances contamination control in critical environments.

  9. Overcoming Capacity Constraints 11/13/2023

    How can CGT biotechs overcome issues such as building an in house facility and ultimately get their therapies to patients.

  10. Scaling Viral Vectors 11/13/2023

    Industry experts cover the high operational costs associated with viral vectors, along with the challenge presented by their shot shelf life and scalability.